Product Description
The drugTM5614 wasoriginally developed in Japan based on the idea that inhibition of PAI-1 might be useful in slowing the progression of kidney disease in patients with diabetes.Based on work done in Vaughans laboratory at Northwestern and in others around the world, evidence shows that PAI-1 contributes to a number of different metabolic, cardiovascular, fibrotic and aging-related disorders. (Sourced from: https://news.northwestern.edu/stories/2020/12/blood-clots-covid-19-patients/&fj=1)
Mechanisms of Action: PAI-1 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Northwestern University
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: COVID-19
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| STOP Severe COVID-19 | P2 |
Suspended |
COVID-19 |
2025-04-23 |